EHA 2015 | HELIOS trial: Ibrutinib combined with BR for previously treated CLL/SLL

Paula Cramer

At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany, discusses the first results from the Phase III HELIOS trial, which evaluated the first-in-class, oral covalent Bruton’s tyrosine kinase inhibitor, ibrutinib, in combination with bendamustine and rituximab (BR) versus BR plus placebo in patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Share this video